Cdkn3-KO Mouse
一般名
Cdkn3-KO
製品ID
S-KO-13928
背景情報
C57BL/6JCya
系統ID
KOCMP-72391-Cdkn3-B6J-VA
状況
このマウス系統を論文で使用する場合は、「Cdkn3-KO Mouse（カタログ番号S-KO-13928）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Cdkn3-KO
系統ID
KOCMP-72391-Cdkn3-B6J-VA
遺伝子名
製品ID
S-KO-13928
遺伝子別名
KAP, 2410006H10Rik
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conventional knockout
染色体
Chr 14
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000067426
NCBIトランスクリプトID
NM_028222
ターゲット領域
Exon 2~6
有効領域の大きさ
~7.7 kb
遺伝子研究の概要
CDKN3, short for cyclin-dependent kinase inhibitor 3, is a dual-specificity protein tyrosine phosphatase. It is involved in important biological processes such as mitosis and cell cycle regulation. It may be associated with several signaling pathways including P53, PI3K-AKT, cell cycle checkpoints, mitotic spindle checkpoint, and chromosome maintenance [6,7]. Understanding CDKN3's function is crucial as it has implications for various biological functions and disease development, and genetic models can be valuable tools for its study.
CDKN3 has been found to be upregulated in multiple cancer types. In cervical cancer, its upregulation is associated with low survival, making it a potential target for therapy [1]. In bladder cancer, CDKN3 promotes proliferation, migration, and confers cisplatin resistance via LDHA-dependent glycolysis reprogramming [2]. In colorectal cancer, it is highly expressed, correlated with poor prognosis, and regulates cisplatin resistance through TIPE1 [3]. In pancreatic cancer, PSMD12 and GID2 interact with CDKN3, affecting its ubiquitination and stability, and facilitating cancer progression [4,8]. In esophageal cancer, CDKN3 promotes tumor progression and cisplatin resistance via RAD51 [5]. In renal cell carcinoma, ZNF677 suppresses cancer progression through transcriptional repression of CDKN3 [9]. In hepatocellular carcinoma, CDKN3 expression is negatively correlated with survival and regulates adriamycin sensitivity [10].
In conclusion, CDKN3 plays a significant role in the cell cycle and mitosis. Model-based research, especially in the context of cancer, has revealed its importance in promoting tumor progression and conferring chemoresistance in various cancers. Understanding CDKN3's functions through these models provides potential therapeutic targets for treating cancers where CDKN3 is aberrantly regulated.
References:
1. Berumen, Jaime, Espinosa, Ana María, Medina, Ingrid. 2014. Targeting CDKN3 in cervical cancer. In Expert opinion on therapeutic targets, 18, 1149-62. doi:10.1517/14728222.2014.941808. https://pubmed.ncbi.nlm.nih.gov/25152075/
2. Li, Mengxuan, Che, Nan, Jin, Yu, Li, Jinhua, Yang, Wanshan. 2022. CDKN3 Overcomes Bladder Cancer Cisplatin Resistance via LDHA-Dependent Glycolysis Reprogramming. In OncoTargets and therapy, 15, 299-311. doi:10.2147/OTT.S358008. https://pubmed.ncbi.nlm.nih.gov/35388272/
3. Li, W-H, Zhang, L, Wu, Y-H. . CDKN3 regulates cisplatin resistance to colorectal cancer through TIPE1. In European review for medical and pharmacological sciences, 24, 3614-3623. doi:10.26355/eurrev_202004_20823. https://pubmed.ncbi.nlm.nih.gov/32329836/
4. Ma, Jia, Zhou, Wenyang, Yuan, Yifeng, Wang, Baosheng, Meng, Xiangpeng. 2023. PSMD12 interacts with CDKN3 and facilitates pancreatic cancer progression. In Cancer gene therapy, 30, 1072-1083. doi:10.1038/s41417-023-00609-y. https://pubmed.ncbi.nlm.nih.gov/37037907/
5. Wang, Jiansong, Che, Wencheng, Wang, Weimin, Zhen, Tianchang, Jiang, Zhongmin. 2019. CDKN3 promotes tumor progression and confers cisplatin resistance via RAD51 in esophageal cancer. In Cancer management and research, 11, 3253-3264. doi:10.2147/CMAR.S193793. https://pubmed.ncbi.nlm.nih.gov/31114363/
6. Chen, Yingjun, Li, Dai, Sha, Kaihui, Zhang, Xuezhong, Liu, Tonggang. 2024. Human pan-cancer analysis of the predictive biomarker for the CDKN3. In European journal of medical research, 29, 272. doi:10.1186/s40001-024-01869-6. https://pubmed.ncbi.nlm.nih.gov/38720365/
7. Zhang, Chuanlong, Shen, Qian, Gao, Mengqi, Li, Junchen, Pang, Bo. 2024. The role of Cyclin Dependent Kinase Inhibitor 3 (CDKN3) in promoting human tumors: Literature review and pan-cancer analysis. In Heliyon, 10, e26061. doi:10.1016/j.heliyon.2024.e26061. https://pubmed.ncbi.nlm.nih.gov/38380029/
8. Deng, Xin, Ma, Jia, Zhou, Wenyang, Wang, Baosheng, Meng, Xiangpeng. 2023. GID2 Interacts With CDKN3 and Regulates Pancreatic Cancer Growth and Apoptosis. In Laboratory investigation; a journal of technical methods and pathology, 103, 100122. doi:10.1016/j.labinv.2023.100122. https://pubmed.ncbi.nlm.nih.gov/36828188/
9. Li, Aolin, Cao, Congcong, Gan, Ying, Yao, Lin, Zhang, Qian. . ZNF677 suppresses renal cell carcinoma progression through N6-methyladenosine and transcriptional repression of CDKN3. In Clinical and translational medicine, 12, e906. doi:10.1002/ctm2.906. https://pubmed.ncbi.nlm.nih.gov/35678231/
10. Dai, Wei, Fang, Shuo, Cai, Guanhe, Liu, Xiaoguang, Li, Mingyi. . CDKN3 expression predicates poor prognosis and regulates adriamycin sensitivity in hepatocellular carcinoma in vitro. In The Journal of international medical research, 48, 300060520936879. doi:10.1177/0300060520936879. https://pubmed.ncbi.nlm.nih.gov/32721244/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。